Summary of Study ST001925
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001215. The data can be accessed directly via it's Project DOI: 10.21228/M8NQ5X This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST001925 |
Study Title | MS Untargeted Metabolomics from Human Serum |
Study Summary | Multiple Myeloma patients were treated with the proteasome inhibitor carfilzomib in different protocols according to their clinical stage. Paired serum samples were obtained before i.v injection and after 1-8h post treatment and snap frozen. Samples were stored at -80°C until analysis. |
Institute | University of Zurich |
Last Name | Mendez |
First Name | Max |
Address | Rorschacherstrasse 95. 9007, St.Gallen |
maxmendez@runbox.com | |
Phone | +41 71 494 10 67 |
Submit Date | 2021-09-21 |
Num Groups | 2 |
Total Subjects | 6 |
Num Males | 5 |
Num Females | 1 |
Raw Data Available | Yes |
Raw Data File Type(s) | raw(Waters) |
Analysis Type Detail | LC-MS |
Release Date | 2022-01-02 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR001215 |
Project DOI: | doi: 10.21228/M8NQ5X |
Project Title: | Metabolic Changes in Multiple Myeloma Patients after CFZ treatment |
Project Type: | MS Untargeted Metabolomics from Human Serum |
Project Summary: | In this study we aimed to examine the acute metabolomic changes following proteasome inhibition with Carfilzomib within 8h of treatment. |
Institute: | University of Zurich |
Department: | Department of Hematology-Oncology. Kantonsspital St. Gallen |
Laboratory: | Experimental Hematolgy-KSSG |
Last Name: | Mendez |
First Name: | Max |
Address: | Rorschacherstrasse 95, 9007, St. Gallen. |
Email: | maxmendez@runbox.com |
Phone: | +41 71 494 10 67 |
Subject:
Subject ID: | SU002003 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Age Or Age Range: | 49-79 years old |
Gender: | Male and female |
Human Medications: | All patients had received at lest 3 lines of anti-myeloma therapy |
Species Group: | Mammals |
Factors:
Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)
mb_sample_id | local_sample_id | class |
---|---|---|
SA178102 | Post1_NEG | POSTREATMENT |
SA178103 | Post1_POS | POSTREATMENT |
SA178104 | Post5_NEG | POSTREATMENT |
SA178105 | Post6_POS | POSTREATMENT |
SA178106 | Post3_NEG | POSTREATMENT |
SA178107 | Post3_POS | POSTREATMENT |
SA178108 | Post5_POS | POSTREATMENT |
SA178109 | Post6_NEG | POSTREATMENT |
SA178110 | Post2_POS | POSTREATMENT |
SA178111 | Post4_POS | POSTREATMENT |
SA178112 | Post2_NEG | POSTREATMENT |
SA178113 | Post4_NEG | POSTREATMENT |
SA178114 | Pre4_POS | PRETREATMENT |
SA178115 | Pre5_POS | PRETREATMENT |
SA178116 | Pre1_POS | PRETREATMENT |
SA178117 | Pre2_POS | PRETREATMENT |
SA178118 | Pre3_POS | PRETREATMENT |
SA178119 | Pre6_POS | PRETREATMENT |
SA178120 | Pre2_NEG | PRETREATMENT |
SA178121 | Pre1_NEG | PRETREATMENT |
SA178122 | Pre6_NEG | PRETREATMENT |
SA178123 | Pre3_NEG | PRETREATMENT |
SA178124 | Pre4_NEG | PRETREATMENT |
SA178125 | Pre5_NEG | PRETREATMENT |
SA178126 | QC_14_POS | QC |
SA178127 | QC_13_POS | QC |
SA178128 | QC_11_POS | QC |
SA178129 | QC_12_POS | QC |
SA178130 | QC_06_POS | QC |
SA178131 | QC_10_NEG | QC |
SA178132 | QC_11_NEG | QC |
SA178133 | QC_09_NEG | QC |
SA178134 | QC_08_NEG | QC |
SA178135 | QC_07_NEG | QC |
SA178136 | QC_12_NEG | QC |
SA178137 | QC_13_NEG | QC |
SA178138 | QC_08_POS | QC |
SA178139 | QC_09_POS | QC |
SA178140 | QC_07_POS | QC |
SA178141 | QC_06_NEG | QC |
SA178142 | QC_14_NEG | QC |
SA178143 | QC_10_POS | QC |
Showing results 1 to 42 of 42 |
Collection:
Collection ID: | CO001996 |
Collection Summary: | Anesthesia was induced with Ketamine 80 mg/kg intramuscular and maintained with Isoflurane 0.5%. Plasma was obtained by centrifugation after cervical dislocation under anesthesia. Samples were snap frozen in dry ice and kept at -80°C until analysis. |
Sample Type: | Blood (plasma) |
Storage Conditions: | Described in summary |
Treatment:
Treatment ID: | TR002015 |
Treatment Summary: | See attached file |
Treatment Compound: | Carfilzomib i.v |
Treatment Route: | i.v |
Treatment Dose: | As described in attached file |
Sample Preparation:
Sampleprep ID: | SP002009 |
Sampleprep Summary: | No. Step 1 Take 40 μL of each sample into the 96-well plate; 2 Insert fetal bovine serum (more than 50, insert one for every 10 samples; 50 or less are not considered); 3 Add 120 μL of pre-cooled methanol, mix and shake for 1 min, and place in a refrigerator at -20°C for 2h or overnight; 4 4,000g * 4°C centrifugation for 30 min; 5 Place 25 μL of each sample in a new 96-well plate and dilute with 225 μL of 50% methanol; 6 Take 50 μL of each sample and mix to QC sample; 7 Take 60 μL of the supernatant and transfer to a 96-well microplate, seal the membrane and test it on the machine. |
Processing Storage Conditions: | -80℃ |
Extract Storage: | -80℃ |
Combined analysis:
Analysis ID | AN003128 | AN003129 |
---|---|---|
Analysis type | MS | MS |
Chromatography type | Reversed phase | Reversed phase |
Chromatography system | Waters Acquity | Waters Acquity |
Column | Waters Acquity BEH HSS T3 (100 x 2.1mm,1.8um) | Waters Acquity BEH HSS T3 (100 x 2.1mm,1.8um) |
MS Type | ESI | ESI |
MS instrument type | Triple quadrupole | Triple quadrupole |
MS instrument name | Waters Xevo-TQ | Waters Xevo-TQ |
Ion Mode | NEGATIVE | POSITIVE |
Units | m/z | m/z |
Chromatography:
Chromatography ID: | CH002311 |
Chromatography Summary: | All samples were acquired by the LC-MS system followed machine orders. Firstly, all chromatographic separations were performed using an ultra performance liquid chromatography (UPLC) system (Waters, UK). An ACQUITY UPLC HSS T3 column (100 mm*2.1 mm, 1.8 μm, Waters, UK) was used for the reversed phase separation. The column oven was maintained at 50 °C. The flow rate was 0.4 ml/min and the mobile phase consisted of solvent A (water + 0.1% formic acid) and solvent B (methanol + 0.1% formic acid). Gradient elution conditions were set as follows: 0~2 min, 100% phase A; 2~11 min, 0% to 100% B; 11~13 min, 100% B; 13~15 min, 0% to 100% A. The injection volume for each sample was 5 µL. |
Instrument Name: | Waters Acquity |
Column Name: | Waters Acquity BEH HSS T3 (100 x 2.1mm,1.8um) |
Flow Gradient: | 0.4 ml/min |
Solvent A: | 100% water; 0.1% formic acid |
Solvent B: | 100% methanol; 0.1% formic acid |
Chromatography Type: | Reversed phase |
MS:
MS ID: | MS002908 |
Analysis ID: | AN003128 |
Instrument Name: | Waters Xevo-TQ |
Instrument Type: | Triple quadrupole |
MS Type: | ESI |
MS Comments: | he additive ions when the substance is ionized at the ion source are negative ions such as COOH-, OH-. , the capillary and sampling cone voltages were set at 2.0 kV and 40.0 V, respectively. |
Ion Mode: | NEGATIVE |
MS ID: | MS002909 |
Analysis ID: | AN003129 |
Instrument Name: | Waters Xevo-TQ |
Instrument Type: | Triple quadrupole |
MS Type: | ESI |
MS Comments: | The additive ions when the substance is ionized at the ion source are positive ions such as H+, NH4+, K+. , the capillary and sampling cone voltages were set at 3.0 kV and 40.0 V, respectively |
Ion Mode: | POSITIVE |